Etrasimod for the treatment of Ulcerative Colitis: Up to 4 years of safety data from the global clinical programme

被引：0
|
作者：
Vermeire, S. [1 ]
Rubin, D. T. [2 ]
Regueiro, M. D. [3 ]
Takeuchi, K. [4 ]
Walsh, A. [5 ]
Kotze, P. G. [6 ]
Charabaty, A. [7 ]
Goetsch, M. [8 ]
Lazin, K. [8 ]
Wu, J. [9 ]
Tsamos, G. [10 ]
Segovia, M. [11 ]
Branquinho, D. [11 ]
Danese, S. [12 ,13 ]
机构：
[1] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
[2] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL USA
[3] Cleveland Clin, Dept Gastroenterol Hepatol & Nutr, Cleveland, OH USA
[4] Tsujinaka Hosp Kashiwanoha, IBD Ctr, Dept Gastroenterol, Kashiwa, Chiba, Japan
[5] Oxford Univ Hosp, Translat Gastroenterol Unit, Oxford, England
[6] Pontificia Univ Catolica Parana PUCPR, IBD Outpatient Clin, Colorectal Surg Unit, Curitiba, Brazil
[7] Johns Hopkins Sch Med, Div Gastroenterol & Hepatol, Washington, DC USA
[8] Pfizer AG, Zurich, Switzerland
[9] Pfizer Inc, Cambridge, MA USA
[10] Pfizer Thessaloniki, Thessaloniki, Cent Macedonia, Greece
[11] Pfizer Inc, New York, NY USA
[12] IRCCS San Raffaele Hosp, Milan, Italy
[13] Univ Vita Salute San Raffaele, Div Gastroenterol & Endoscopy, Milan, Italy
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.0057
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP018
引用
收藏
页码：i115 / i117
页数：3
相关论文
共 50 条
  • [21] Assessment and Impact of Age on the Safety and Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From the ELEVATE UC Clinical Program
    Lichtenstein, Gary R.
    Allegretti, Jessica R.
    Loftus Jr, Edward, V
    Irving, Peter M.
    Banerjee, Rupa
    Charabaty, Aline
    Kuehbacher, Tanja
    Bananis, Eustratios
    Woolcott, John C.
    Dalam, Alexis B.
    Lazin, Krisztina
    Keating, Michael
    Mcdonnell, Aoibhinn
    Danese, Silvio
    INFLAMMATORY BOWEL DISEASES, 2025,
  • [22] The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme
    Sands, B. E.
    Taub, P. R.
    Feagan, B. G.
    Armuzzi, A.
    Friedman, G. S.
    Moscariello, M.
    Lawendy, N.
    Pedersen, R. D.
    Chan, G.
    Nduaka, C. I.
    Quirk, D.
    Salese, L.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S23 - S23
  • [23] Characterisation of hospitalised patients with ulcerative colitis treated with tofacitinib in the OCTAVE clinical programme for up to 7.8 years
    Taxonera, C.
    Ha, C.
    Fortes, M. del Pilar
    Gardiner, S.
    Mundayat, R.
    Ghosh, S.
    Connor, S. J.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 678 - 679
  • [24] The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data
    Cohen, Russell D.
    Bhayat, Fatima
    Blake, Aimee
    Travis, Simon
    JOURNAL OF CROHNS & COLITIS, 2020, 14 (02): : 192 - 204
  • [25] Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programme
    Rubin, D. T.
    Torres, J.
    Regueiro, M.
    Reinisch, W.
    Prideaux, L.
    Kotze, P. G.
    Tan, F. H.
    Gardiner, S.
    Mundayat, R.
    Cadatal, M. J.
    Ng, S. C.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I506 - I507
  • [26] Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programme
    Rubin, D. T.
    Torres, J.
    Regueiro, M.
    Reinisch, W.
    Prideaux, L.
    Kotze, P. G.
    Tan, F. H.
    Gardiner, S.
    Mundayat, R.
    Cadatal, M. J.
    Ng, S. C.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I506 - I507
  • [27] The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme
    Sands, B. E.
    Taub, P. R.
    Feagan, B. G.
    Armuzzi, A.
    Damiao, A. O.
    Lawendy, N.
    Solano, G.
    Kwok, K.
    Woolcott, J.
    Salese, L.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S557 - S558
  • [28] Safety of Adalimumab in Global Clinical Trials of Ulcerative Colitis Patients
    Colombel, Jean-Frederic
    Ghosh, Subrata
    Sandborn, William
    Van Assche, Gert A.
    Reinisch, Walter
    Lazar, Andreas
    Eichner, Samantha
    Huang, Bidan
    Robinson, Anne
    Thakkar, Roopal
    GASTROENTEROLOGY, 2013, 144 (05) : S231 - S232
  • [29] Tofacitinib for the treatment of ulcerative colitis: analysis of malignancy rates from the OCTAVE clinical programme
    Lichtenstein, G. R.
    Ciorba, M. A.
    Rogler, G.
    Quirk, D.
    Nduaka, C. I.
    Pedersen, R. D.
    Lawendy, N.
    Chan, G.
    Su, C.
    Panes, J.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S48 - S49
  • [30] Tofacitinib for the treatment of ulcerative colitis: Analysis of infection rates from the OCTAVE clinical programme
    Winthrop, K. L.
    Loftus, E. V., Jr.
    Baumgart, D. C.
    Reinisch, W.
    Thorpe, A. J.
    Nduaka, C. I.
    Lawendy, N.
    Chan, G.
    Pedersen, R. D.
    Friedman, G. S.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S351 - S352
12345